AIM: @entity788 remains one of the @entity5 diagnoses and is the fourth leading cause of @entity5 in the U.S. Surgery is the mainstay of treatment for the 20% for whom the @entity5 is resectable, however, controversy exists over the appropriate adjuvant therapy where local recurrence rates remain strikingly high (50-85%). We aimed to evaluate the safety and efficacy of adding @entity416 (a known radiosensitizer by direct and abscopal effects) to concurrent radiation in the adjuvant setting after resection of @entity788 . @entity1 AND METHODS: We conducted a retrospective study of 63 @entity1 diagnosed from 2004-2013 with histopathologically-confirmed @entity5 treated with a surgical resection followed by adjuvant concurrent chemoradiation to at least 45 Gy using 3D planning and @entity416 at 1,600 mg/m(2)/day (Monday-Friday) for 6 weeks. This was combined with either 4 months of @entity136 at 1,000 mg/m(2) weekly for 3 out of 4 weeks or @entity416 at 2,000 mg/m(2) for 14 days every 3 weeks for a total of 4 months. RESULTS: The majority of @entity1 were over 65 years old (71%), male (60%), had negative surgical margins (79%), had pancreatic head or neck involvement (71%), Eastern Cooperative Oncology Group performance score of 1 (71%), and a cancer antigen 19-9 in the range of 11-100 U/ml at the time of diagnosis (51%). Of the 63 @entity1 reviewed, 61 @entity1 (97%) completed concurrent chemoradiotherapy. Treatment was halted in one @entity1 due to @entity3621 and a second for @entity360 . Otherwise, adverse reactions during concurrent chemoradiotherapy were well-tolerated and the majority were Common Terminology Criteria for Adverse Events grades 1 and 2. Grade 3 @entity137 was @entity448 (n=2) and @entity8566 (n=2) and @entity548 (n=1). The only grade 4 @entity137 were @entity448 (n=1) and @entity1295 (n=1). The median follow-up of @entity1 at the time of analysis was 36 months. The median survival of the entire cohort was 23.5 (range=8.5-42) months. The 1-, 2- and 3-year survival rates were 80%, 35% and 25%, respectively. CONCLUSION: Concurrent chemoradiation using @entity416 as a radiosensitizer in the adjuvant setting for @entity788 was completed by the vast majority of @entity1 in this series. Treatment was relatively well-tolerated, and its efficacy seems comparable to that for historical controls. This study probably represents the largest yet reported using @entity416 in this setting. Future studies including an increased sample size are required.

@entity416 as a Radiosensitizer in Adjuvant Chemoradiotherapy for XXXX : A Retrospective Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic cancer', 'pancreatic cancer', 'pancreatic adenocarcinoma'] @entity360 :: ('MESH:D006471', 'Disease') :: ['gastrointestinal bleeding'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity548 :: ('MESH:D006470', 'Disease') :: ['GI bleeding'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage I/II pancreatic cancer', 'tumor', 'cancer-related deaths', 'deadliest cancer'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity3621 :: ('MESH:D005756', 'Disease') :: ['gastritis'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand and foot syndrome'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity788 :: (MESH:D010190,Disease) :: ['Pancreatic Cancer']
